Crystal Structures of the Lyn Protein Tyrosine Kinase Domain in Its Apo- and Inhibitor-bound State*

The Src-family protein-tyrosine kinase (PTK) Lyn is the most important Src-family kinase in B cells, having both inhibitory and stimulatory activity that is dependent on the receptor, ligand, and developmental context of the B cell. An important role for Lyn has been reported in acute myeloid leukemia and chronic myeloid leukemia, as well as certain solid tumors. Although several Src-family inhibitors are available, the development of Lyn-specific inhibitors, or inhibitors with reduced off-target activity to Lyn, has been hampered by the lack of structural data on the Lyn kinase. Here we report the crystal structure of the non-liganded form of Lyn kinase domain, as well as in complex with three different inhibitors: the ATP analogue AMP-PNP; the pan Src kinase inhibitor PP2; and the BCR-Abl/Src-family inhibitor Dasatinib. The Lyn kinase domain was determined in its “active” conformation, but in the unphosphorylated state. All three inhibitors are bound at the ATP-binding site, with PP2 and Dasatinib extending into a hydrophobic pocket deep in the substrate cleft, thereby providing a basis for the Src-specific inhibition. Analysis of sequence and structural differences around the active site region of the Src-family PTKs were evident. Accordingly, our data provide valuable information for the further development of therapeutics targeting Lyn and the important Src-family of kinases.

[1]  N. Donato,et al.  Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. , 2008, Blood.

[2]  P. Gopalakrishnakone,et al.  Proteomic analysis of the venom of Heterometrus longimanus (Asian black scorpion) , 2008, Proteomics.

[3]  C. Récher,et al.  A critical role for Lyn in acute myeloid leukemia. , 2008, Blood.

[4]  J. Schneider,et al.  Csk-binding Protein Mediates Sequential Enzymatic Down-regulation and Degradation of Lyn in Erythropoietin-stimulated Cells* , 2006, Journal of Biological Chemistry.

[5]  Matthew B. Wilson,et al.  Src Family Kinases Phosphorylate the Bcr-Abl SH3-SH2 Region and Modulate Bcr-Abl Transforming Activity* , 2006, Journal of Biological Chemistry.

[6]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[7]  M. Wittekind,et al.  The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. , 2006, Cancer research.

[8]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[9]  W. Erber,et al.  Lyn deficiency reduces GATA-1, EKLF and STAT5, and induces extramedullary stress erythropoiesis , 2005, Oncogene.

[10]  C. Quilici,et al.  Perturbed myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1. , 2004, Blood.

[11]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[12]  A. Gewirtz,et al.  Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells , 2004, Nature Medicine.

[13]  J. Parsons,et al.  Src family kinases, key regulators of signal transduction , 2004, Oncogene.

[14]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[15]  J. Drachman,et al.  Lyn tyrosine kinase regulates thrombopoietin-induced proliferation of hematopoietic cell lines and primary megakaryocytic progenitors. , 2004, Blood.

[16]  S. Ben‐Sasson,et al.  Lyn Is a Target Gene for Prostate Cancer , 2004, Cancer Research.

[17]  D. Fabbro,et al.  Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. , 2003, Blood.

[18]  N. Donato,et al.  BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. , 2003, Blood.

[19]  D. Boschelli,et al.  SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. , 2003, Cancer research.

[20]  Matthew B. Wilson,et al.  Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr–Abl signal transduction and oncogenesis , 2002, Oncogene.

[21]  S. Rane,et al.  JAKs, STATs and Src kinases in hematopoiesis , 2002, Oncogene.

[22]  D. Chappell,et al.  Thyroid Hormone Receptor-interacting Protein 1 Modulates Cytokine and Nuclear Hormone Signaling in Erythroid Cells* , 2001, The Journal of Biological Chemistry.

[23]  D. Fisher,et al.  A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. , 2001, Cancer research.

[24]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[25]  J. Williams,et al.  Maturation of erythroid cells and erythroleukemia development are affected by the kinase activity of Lyn. , 2001, Cancer research.

[26]  F. Giancotti,et al.  Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. , 2000, The Journal of clinical investigation.

[27]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[28]  L. Toledo,et al.  Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. , 2000, Structure.

[29]  T. Pawson,et al.  Protein-protein interactions define specificity in signal transduction. , 2000, Genes & development.

[30]  S. Klinken,et al.  HS1 Interacts with Lyn and Is Critical for Erythropoietin-induced Differentiation of Erythroid Cells* , 2000, The Journal of Biological Chemistry.

[31]  J. Kuriyan,et al.  Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. , 1999, Molecular cell.

[32]  S. Harrison,et al.  Crystal structures of c-Src reveal features of its autoinhibitory mechanism. , 1999, Molecular cell.

[33]  N. Miyasaka,et al.  Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. , 1998, Blood.

[34]  C. Deberry,et al.  Lyn Associates with the Juxtamembrane Region of c-Kit and Is Activated by Stem Cell Factor in Hematopoietic Cell Lines and Normal Progenitor Cells* , 1997, The Journal of Biological Chemistry.

[35]  S. Klinken,et al.  Lyn tyrosine kinase is essential for erythropoietin‐induced differentiation of J2E erythroid cells , 1997, The EMBO journal.

[36]  John Kuriyan,et al.  Crystal structure of the Src family tyrosine kinase Hck , 1997, Nature.

[37]  Michael J. Eck,et al.  Three-dimensional structure of the tyrosine kinase c-Src , 1997, Nature.

[38]  O. Olivieri,et al.  Deficiency of Src family kinases Fgr and Hck results in activation of erythrocyte K/Cl cotransport. , 1997, The Journal of clinical investigation.

[39]  Hiroto Yamaguchi,et al.  Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation , 1996, Nature.

[40]  S. Stacker,et al.  Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease , 1995, Cell.

[41]  E. Ingley,et al.  Src family kinases: regulation of their activities, levels and identification of new pathways. , 2008, Biochimica et biophysica acta.

[42]  S. Corey,et al.  Src-related protein tyrosine kinases in hematopoiesis. , 1999, Blood.